L01AA09 • bendamustine • Antineoplastic and immunomodulating agents | Alkylating agents | Nitrogen mustard analogues
Bendamustinum is a medication used for the treatment of certain types of cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. It is an alkylating chemotherapeutic agent that interferes with the DNA of cancer cells, inhibiting cell division and causing cell death.
The medication is administered via intravenous infusion, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer and the patient's response.
Common side effects include nausea, vomiting, fatigue, decreased blood cell counts, and infections. In rare cases, more severe adverse effects such as liver failure or severe allergic reactions may occur.
Bendamustinum is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
Substance: bendamustine
Date of last drug list: 01-10-2015
Commercial code: W61925001
Concentration: 2.5mg / ml
Pharmaceutical form: powder for concentrate infusion solution
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).